2-(1-ethyl-propoxy)-phenylamine | 640767-47-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(1-ethyl-propoxy)-phenylamine
• 英文别名: 2-(Pentan-3-yloxy)aniline；2-pentan-3-yloxyaniline
• CAS: 640767-47-1
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: HOVIGOFLFFJROL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1-ethyl-propoxy)-phenylamine 在 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 1,2-二氯乙烷 、 异丙醇 为溶剂， 生成 [3-({2-[2-(1-ethyl-propoxy)-phenylamino]-ethylamino}-methyl)-phenyl]-piperidin-1-yl-methanone
  参考文献：
  名称：

  Inhibitors of the glycine transporter type-2 (GlyT-2): synthesis and biological activity of benzoylpiperidine derivatives

  摘要：

  A series of benzoylpiperidine analogs related to 4a was prepared, and their ability to inhibit the uptake of [C-14]-glycine in COS7 cells transfected with human glycine transporter type-2 (GlyT-2) was evaluated. Small structural changes to the benzoylpiperidine region of the molecule led to a significant decrease in GlyT-2 inhibitory activity. In contrast, the distal aryl ring was more tolerant to functional group modifications and could accommodate a variety of substitutes at the C-2 or C-3 positions. Comparable activities to 4a were obtained by replacing the anilino nitrogen with an ether linkage 27 or by exchanging the isopropoxy ether moiety with an isopropyl amino group 15. A distinct preference for a 2-carbon tether (n = 1) was observed relative to the corresponding 3-carbon homolog (n = 2). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.044
• 作为产物：
  描述：

  3-碘戊烷 在 sodium disulfite 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(1-ethyl-propoxy)-phenylamine
  参考文献：
  名称：

  Inhibitors of the glycine transporter type-2 (GlyT-2): synthesis and biological activity of benzoylpiperidine derivatives

  摘要：

  A series of benzoylpiperidine analogs related to 4a was prepared, and their ability to inhibit the uptake of [C-14]-glycine in COS7 cells transfected with human glycine transporter type-2 (GlyT-2) was evaluated. Small structural changes to the benzoylpiperidine region of the molecule led to a significant decrease in GlyT-2 inhibitory activity. In contrast, the distal aryl ring was more tolerant to functional group modifications and could accommodate a variety of substitutes at the C-2 or C-3 positions. Comparable activities to 4a were obtained by replacing the anilino nitrogen with an ether linkage 27 or by exchanging the isopropoxy ether moiety with an isopropyl amino group 15. A distinct preference for a 2-carbon tether (n = 1) was observed relative to the corresponding 3-carbon homolog (n = 2). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.044

文献信息

• Aryl piperidine amides
  申请人：Huang Q. Charles

  公开号：US20050049239A1

  公开（公告）日：2005-03-03

  The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.

  该发明提供了新颖的GlyT2抑制化合物，可用于调节、治疗或预防：焦虑症；需要治疗受伤哺乳动物神经组织的状况；适合通过神经营养因子管理治疗的状况；神经系统紊乱；或肥胖症；与肥胖相关的疾病。
• Aryl carbonyl derivatives as therapeutic agents
  申请人：——

  公开号：US20040122235A1

  公开（公告）日：2004-06-24

  This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

  本发明涉及芳基羰基衍生物，其是葡萄糖激酶的激活剂，可用于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。
• Aryl Piperidine Amides
  申请人：Huang Q. Charles

  公开号：US20080009521A1

  公开（公告）日：2008-01-10

  The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.

  本发明提供了新型GlyT2抑制化合物，可用于调节、治疗或预防：抗焦虑障碍；需要治疗受损哺乳动物神经组织的状况；可通过给予神经营养因子进行治疗的状况；神经系统疾病；或肥胖症；肥胖相关疾病。
• ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS
  申请人：Polisetti Dharma Rao

  公开号：US20110301158A1

  公开（公告）日：2011-12-08

  This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

  本发明涉及芳基羰基衍生物，它们是葡萄糖激酶的活化剂，可能有助于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。
• USRE045670E1
  申请人：——

  公开号：——

  公开（公告）日：——